Results 31 to 40 of about 11,222 (199)
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD : a systematic review and meta-analysis [PDF]
, 2017 Acknowledgments The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing
Altman, Pablo +8 more
core +2 more sources
Bulletin of Faculty of Pharmacy Cairo University, 2012 A new simple, accurate, precise, rapid and economical method was developed for the simultaneous determination of Salmeterol xinafoate and Fluticasone propionate in their binary mixture in bulk powder and Seritide diskus® inhalation.
Ahmed Samir +2 more
doaj +1 more source
Italian Journal of Medicine, 2023 Common inflammatory conditions of the airways, such as chronic rhinitis, nasal polyposis, and seasonal and chronic allergic rhinitis, can significantly impact the health and quality of life of a patient.
Yasir Mehmood, Hira Shahid
doaj +1 more source
Withdrawal from treatment as an outcome in the Isolde study of COPD [PDF]
, 2003 Objectives: To investigate the determinants of patient withdrawal from our study, and the effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in patients with COPD.
American Thoracic Society +27 more
core +1 more source
Corticosteroids for the common cold [PDF]
, 2015 BACKGROUND: The common cold is a frequent illness, which, although benign and self limiting, results in many consultations to primary care and considerable loss of school or work days. Current symptomatic treatments have limited benefit.
Del Mar, Chris B. +5 more
core +1 more source
Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. [PDF]
, 2020 BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at risk of exacerbations and pneumonia; how the risk factors interact is unclear.
A Anzueto +42 more
core +2 more sources
Scientific Reports, 2022 The most classic treatment recommended in the current chronic obstructive pulmonary disease (COPD) guidelines is glucocorticoid and β2 receptor agonist combination, such as salmeterol xinafoate and fluticasone propionate (Sal/Flu), causing many adverse ...
Ye Yang +3 more
doaj +1 more source
Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease [PDF]
, 2002 In a double blind randomised controlled trial, 30 infants with chronic lung disease received fluticasone propionate or placebo for one year. There were no significant differences between treatment groups in the incidence of any day or night time symptoms
Beresford, M.W. +3 more
core +2 more sources
International Journal of COPD, 2021 Jae-Hwa Choi,1,* Keun-Bae Jeong,1,* You Hyun Park,2 Iseul Yu,1 Seok Jeong Lee,1 Myoung Kyu Lee,1 Sang-Ha Kim,1 Won-Yeon Lee,1 Suk Joong Yong,1 Ji-Ho Lee1 1Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea;
Choi JH +9 more
doaj
Efficacy of fluticasone propionate ointment 0.005% in childhood lichen planus
Indian Journal of Paediatric Dermatology, 2020 Background: Treatment of childhood lichen planus (LP) is challenging owing to high rate of relapses. Moreover, majority of treatment options for LP have been extrapolated from studies done in adults.
Abhinav Kumar +3 more
doaj +1 more source